Full Text View
Tabular View
No Study Results Posted
Related Studies
Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension
This study has been completed.
Study NCT00095394   Information provided by Bristol-Myers Squibb

First Received on November 3, 2004.   Last Updated on April 7, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hypertension
More general conditions related to this trial
Cardiovascular Diseases
Vascular Diseases
Interventions listed in this trial
Irbesartan/HCTZ
Irbesartan monotherapy
Additional drug interventions recognized in this trial
Hydrochlorothiazide
Irbesartan
More general drug interventions related to this trial
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Antihypertensive Agents
Cardiovascular Agents
Diuretics
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Bristol-Myers Squibb
Sanofi


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services